Velavigo Bio Inc
Clinical trials sponsored by Velavigo Bio Inc, explained in plain language.
-
New drug targets two cancer proteins in advanced tumors
Disease control Not yet recruitingThis trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…
Phase: PHASE1, PHASE2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New Dual-Targeting drug VBC106 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…
Phase: PHASE1, PHASE2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC